Studies have found that HSP90 inhibitors can improve pulmonary arteriole remodeling by inhibiting the extensive proliferation of PASMCs; thus, inhibiting HSP90 may be an effective treatment for PAH [74]. This evidence concerns the gene HSP90AA1 and pulmonary arterial hypertension.